D2-like dopamine receptor · PROTEIN FAMILY · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13D2-like dopamine receptor shows approved-linked disease relevance led by schizophrenia. 5 more disease programs remain visible in the same review block. 11 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P14416. Start with schizophrenia, then reuse UniProt P14416 as the stable protein anchor across project notes and exports.
Start with schizophrenia, then reuse UniProt P14416 as the stable protein anchor across project notes and exports.
D2-like dopamine receptor shows approved-linked disease relevance led by schizophrenia. 5 more disease programs remain visible in the same review block. 11 linked drugs remain visible in the same block.
Start review with schizophrenia because it currently carries approved-linked support. Linked drugs include CHLORPROMAZINE, HALOPERIDOL, HALOPERIDOL DECANOATE, HALOPERIDOL LACTATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyD(2) dopamine receptor
Review this target as D2-like dopamine receptor, mapped to UniProt P14416. ChEMBL maps the protein component as D(2) dopamine receptor. Sequence length is 443 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats D2-like dopamine receptor as ChEMBL target CHEMBL2331075, mapped to UniProt P14416. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether D2-like dopamine receptor is the right protein anchor across sources, using UniProt P14416 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why schizophrenia is currently framed as approved-linked support. It currently carries 11 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | D2-like dopamine receptor |
| Target Type | PROTEIN FAMILY |
| Organism | Homo sapiens |
| UniProt | P14416 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | D(2) dopamine receptor |
| UniProt Accession | P14416 |
| Component Type | Protein |
| Sequence Length | 443 aa |
D(2) dopamine receptor
Review this target as D2-like dopamine receptor, mapped to UniProt P14416. ChEMBL maps the protein component as D(2) dopamine receptor. Sequence length is 443 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
D2-like dopamine receptor shows approved-linked disease relevance led by schizophrenia. 5 more disease programs remain visible in the same review block.
Start review with schizophrenia because it currently carries approved-linked support. Linked drugs include CHLORPROMAZINE, HALOPERIDOL, HALOPERIDOL DECANOATE, HALOPERIDOL LACTATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.